Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas

Boehme,Karen   A.; Nitsch,Juliane; Riester,Rosa; Handgretinger,Rupert; Schleicher,Sabine   B.; Kluba,Torsten; Traub,Frank

doi:10.3892/ijo.2016.3700

Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas

Authors:
- Karen A. Boehme
- Juliane Nitsch
- Rosa Riester
- Rupert Handgretinger
- Sabine B. Schleicher
- Torsten Kluba
- Frank Traub
View Affiliations

Affiliations: Laboratory of Cell Biology, Department of Orthopaedic Surgery, Eberhard Karls University Tuebingen, Tuebingen, Germany, Department of Haematology and Oncology, Children's Hospital, Eberhard Karls University Tuebingen, Tuebingen, Germany, Department of Orthopaedic Surgery, Eberhard Karls University Tuebingen, Tuebingen, Germany
Published online on: September 21, 2016 https://doi.org/10.3892/ijo.2016.3700
Pages: 2135-2146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ewing sarcomas (ES) are rare mesenchymal tumours, most commonly diagnosed in children and adolescents. Arsenic trioxide (ATO) has been shown to efficiently and selectively target leukaemic blasts as well as solid tumour cells. Since multidrug resistance often occurs in recurrent and metastatic ES, we tested potential additive effects of ATO in combination with the cytostatic drugs etoposide and doxorubicin. The Ewing sarcoma cell lines A673, RD-ES and SK-N-MC as well as mesenchymal stem cells (MSC) for control were treated with ATO, etoposide and doxorubicin in single and combined application. Viability and proliferation (MTS assay, colony formation, 3D spheroid culture) as well as cell death induction (western blot analysis, flow cytometry) were analysed. In the MTS viability assays ATO treatment significantly reduced the metabolic activity of all three ES cell lines (A673, RD-ES and SK-N-MC) examined. Moreover, all ES cell lines were sensitive to etoposide, whereas MSC remained unaffected by the drug concentrations used. With the exception of ATO in RD-ES cells, all drugs induced apoptosis in the ES cell lines, indicated by caspase-3 and PARP cleavage. Combination of the agents potentiated the reduction of viability as well as the inhibitory effect on clonal growth. In addition, cell death induction was obviously enhanced in RD-ES and SK-N-MC cells by a combination of ATO and etoposide compared to single application. Summarised, the combination of low dose, physiologically easily tolerable ATO with commonly used etoposide and doxorubicin concentrations efficiently and selectively suppressed viability and colony formation in ES cell lines, whereas a combination of ATO and etoposide was favourable for cell death induction. In addition to an increase of the effectiveness of the cytostatic drugs and prevention of potential drug resistance, this approach may also reduce toxicity effects, since the individual doses can be reduced.

View Figures

View References

1	Jiang Y, Ludwig J and Janku F: Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev. 41:391–400. 2015. View Article : Google Scholar : PubMed/NCBI
2	de Alava E and Gerald WL: Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol. 18:204–213. 2000.PubMed/NCBI
3	Cidre-Aranaz F and Alonso J: EWS/FLI1 target genes and therapeutic opportunities in Ewing sarcoma. Front Oncol. 5:1622015. View Article : Google Scholar : PubMed/NCBI
4	Toomey EC, Schiffman JD and Lessnick SL: Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 29:4504–4516. 2010. View Article : Google Scholar : PubMed/NCBI
5	Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR and Lessnick SL: Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 9:405–416. 2006. View Article : Google Scholar : PubMed/NCBI
6	Liebner DA: The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma. J Surg Oncol. 111:622–631. 2015. View Article : Google Scholar : PubMed/NCBI
7	Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, et al; European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: Two randomized trials of Ewing's sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 26:4385–4393. 2008. View Article : Google Scholar : PubMed/NCBI
8	May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER and Reynolds CP: Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One. 8:e800602013. View Article : Google Scholar : PubMed/NCBI
9	Oda Y, Dockhorn-Dworniczak B, Jürgens H and Roessner A: Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone. J Cancer Res Clin Oncol. 123:237–239. 1997. View Article : Google Scholar : PubMed/NCBI
10	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
11	Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J and Uren A: GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem. 284:9074–9082. 2009. View Article : Google Scholar : PubMed/NCBI
12	Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, Lawlor ER and May WA: GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One. 4:e76082009. View Article : Google Scholar : PubMed/NCBI
13	Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ and May WA: The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene. 27:3282–3291. 2008. View Article : Google Scholar
14	Boehme KA, Zaborski JJ, Riester R, Schweiss SK, Hopp U, Traub F, Kluba T, Handgretinger R and Schleicher SB: Targeting hedgehog signalling by arsenic trioxide reduces cell growth and induces apoptosis in rhabdomyosarcoma. Int J Oncol. 48:801–812. 2016.
15	Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, et al: Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 121:148–160. 2011. View Article : Google Scholar :
16	Zhang S, Guo W, Ren TT, Lu XC, Tang GQ and Zhao FL: Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase. Anticancer Drugs. 23:108–118. 2012. View Article : Google Scholar
17	Matsumoto T, Tabata K and Suzuki T: The GANT61, a GLI inhibitor, induces caspase-independent apoptosis of SK-N-LO cells. Biol Pharm Bull. 37:633–641. 2014. View Article : Google Scholar : PubMed/NCBI
18	Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, Müller I, Schewe B, Skutella T, Fibbe WE, et al: Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica. 94:173–184. 2009. View Article : Google Scholar :
19	Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I and Szijan I: Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med. 16:262–270. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kelleher FC, Cain JE, Healy JM, Watkins DN and Thomas DM: Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther. 136:153–168. 2012. View Article : Google Scholar : PubMed/NCBI
21	Amakye D, Jagani Z and Dorsch M: Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 19:1410–1422. 2013. View Article : Google Scholar : PubMed/NCBI
22	Lin PP, Wang Y and Lozano G: Mesenchymal stem cells and the origin of Ewing's sarcoma. Sarcoma. 2011:2764632011. View Article : Google Scholar
23	Sand LG, Szuhai K and Hogendoorn PC: Sequencing overview of Ewing sarcoma: A journey across genomic, epigenomic and transcriptomic landscapes. Int J Mol Sci. 16:16176–16215. 2015. View Article : Google Scholar : PubMed/NCBI
24	Aberger F and Ruiz I Altaba A: Context-dependent signal integration by the GLI code: The oncogenic load, pathways, modifiers and implications for cancer therapy. Semin Cell Dev Biol. 33:93–104. 2014. View Article : Google Scholar : PubMed/NCBI
25	Watts JM and Tallman MS: Acute promyelocytic leukemia: What is the new standard of care? Blood Rev. 28:205–212. 2014. View Article : Google Scholar : PubMed/NCBI
26	Raju GP: Arsenic: A potentially useful poison for Hedgehog-driven cancers. J Clin Invest. 121:14–16. 2011. View Article : Google Scholar :
27	Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, et al: Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 23:23–34. 2013. View Article : Google Scholar : PubMed/NCBI
28	Au WY, Tam S, Fong BM and Kwong YL: Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 112:3587–3590. 2008. View Article : Google Scholar : PubMed/NCBI
29	Mathieu J and Besançon F: Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells. Int J Cancer. 119:1723–1727. 2006. View Article : Google Scholar : PubMed/NCBI
30	Emadi A and Gore SD: Arsenic trioxide - An old drug rediscovered. Blood Rev. 24:191–199. 2010. View Article : Google Scholar : PubMed/NCBI
31	Sordet O, Liao Z, Liu H, Antony S, Stevens EV, Kohlhagen G, Fu H and Pommier Y: Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis. J Biol Chem. 279:33968–33975. 2004. View Article : Google Scholar : PubMed/NCBI
32	Tan B, Piwnica-Worms D and Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol. 12:450–458. 2000. View Article : Google Scholar : PubMed/NCBI
33	Melguizo C, Prados J, Rama AR, Ortiz R, Álvarez PJ, Fernández JE and Aranega A: Multidrug resistance and rhabdomyosarcoma (Review). Oncol Rep. 26:755–761. 2011.PubMed/NCBI
34	Santisteban M: ABC transporters as molecular effectors of pancreatic oncogenic pathways: The Hedgehog-GLI model. J Gastrointest Cancer. 41:153–158. 2010. View Article : Google Scholar : PubMed/NCBI
35	Leslie EM, Haimeur A and Waalkes MP: Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem. 279:32700–32708. 2004. View Article : Google Scholar : PubMed/NCBI
36	Feng T, Qiao G, Feng L, Qi W, Huang Y, Yao Y and Shen Z: Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells. Mol Med Rep. 10:2985–2992. 2014.PubMed/NCBI
37	Guo W, Tang XD, Tang S and Yang Y: Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma. Zhonghua Wai Ke Za Zhi. 44:805–808. 2006.(In Chinese). PubMed/NCBI
38	Zhao YY, Yu L, Liu BL, He XJ and Zhang BY: Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines. Mol Med Rep. 12:7335–7343. 2015.PubMed/NCBI